Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 26, 2023

BUY
$118.5 - $160.53 $2,725 - $3,692
23 Added 0.78%
2,988 $363,000
Q1 2023

May 04, 2023

BUY
$135.66 - $197.02 $24,961 - $36,251
184 Added 6.62%
2,965 $455,000
Q4 2022

Feb 14, 2023

BUY
$118.38 - $210.04 $72,448 - $128,544
612 Added 28.22%
2,781 $499,000
Q3 2022

Nov 04, 2022

SELL
$118.07 - $194.18 $5,549 - $9,126
-47 Reduced 2.12%
2,169 $257,000
Q2 2022

Jul 26, 2022

BUY
$117.13 - $176.59 $54,231 - $81,761
463 Added 26.41%
2,216 $317,000
Q1 2022

May 16, 2022

BUY
$126.46 - $235.05 $92,568 - $172,056
732 Added 71.69%
1,753 $304,000
Q4 2021

Feb 15, 2022

SELL
$225.82 - $368.51 $228,078 - $372,195
-1,010 Reduced 49.73%
1,021 $259,000
Q3 2021

Oct 12, 2021

BUY
$221.9 - $484.47 $91,200 - $199,117
411 Added 25.37%
2,031 $782,000
Q2 2021

Jul 13, 2021

SELL
$129.91 - $234.98 $13,250 - $23,967
-102 Reduced 5.92%
1,620 $380,000
Q1 2021

Apr 14, 2021

SELL
$109.18 - $185.98 $90,619 - $154,363
-830 Reduced 32.52%
1,722 $226,000
Q4 2020

Jan 12, 2021

BUY
$65.74 - $169.86 $167,768 - $433,482
2,552 New
2,552 $267,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Cypress Capital Group Portfolio

Follow Cypress Capital Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cypress Capital Group, based on Form 13F filings with the SEC.

News

Stay updated on Cypress Capital Group with notifications on news.